|
Marker | Full name | Cancer types | Detection type | Clinical applications | Year of FDA approval |
|
AFP | α-Fetoprotein | Liver | Protein concentrations and core fucosylation (for AFP-L3) | Diagnosis, staging, detecting recurrence, and monitoring therapy | 1992/2008 |
|
PSA, Pro2PSA | Prostate-specific antigen | Prostate | Protein concentrations | Screening, discriminating cancer from benign disease | 1986/1994/ 2012 |
|
CA125 (MUC16) | Cancer antigen 125 | Ovarian | Protein concentrations | Monitoring therapy, detecting recurrence | 1997/2011 |
|
HE4 (WFDC2) | Human epididymis protein 4 | Ovarian | Protein concentrations | Monitoring therapy, detecting recurrence | 2008 |
|
OVA1 test (multiple proteins) | -2 Microglobulin + CA 125II (up), apolipoprotein A1 + prealbumin + transferrin (down) | Ovarian | Protein concentrations | Prediction | 2009 |
|
ROMA test | HE4 + CA125 | Ovarian | Protein concentrations | Prediction | 2011 |
|
CA15-3 (MUC1) | Cancer antigen 15-3 | Breast | Sialylated O-linked oligosaccharide on MUC1 | Monitoring therapy | 1997 |
|
CA27-29 | Cancer antigen 27-29 | Breast | MUC1 protein levels | Monitoring therapy | 2002 |
|
CA19-9 | Carbohydrate antigen 19-9 or cancer antigen 19-9 | Pancreatic, ovarian | SLea on mucin glycoproteins and gangliosides | Monitoring therapy | 2002 |
|
CEA | Carcinoembryonic antigen | Colon, gastric, pancreatic, lung, and breast | Protein concentrations | Monitoring therapy, detecting recurrence | 1985 |
|
HER2/neu | Human epidermal growth factor receptor 2 | Breast | Protein concentrations | Therapy choice | 1998 |
|
Tg | Thyroglobulin | Thyroid | Protein concentrations | Monitoring therapy | 1997 |
|
hCG | Human chorionic gonadotropin | Testicular, ovarian | Protein concentrations | Diagnosis, staging, detecting recurrence, and monitoring therapy | Not approved |
|